FOMAT Launches Phase 1 Services, Elevating Site Operations and Improving Patient Diversity in Early-Stage Trials
FOMAT Medical Research has officially launched its new Phase I capabilities, marking a significant expansion in its service offerings. This milestone brings advanced early-phase clinical trial services to underserved communities, showcasing FOMAT’s commitment to innovation and diversity in clinical research.
Expanding Phase I Capabilities to Better Serve Patients and Industry
Today, FOMAT unveiled its Phase I services, featuring state-of-the-art facilities and specialized staff that allow for a comprehensive range of early-phase clinical trials. These services include pharmacokinetic and pharmacodynamic studies, as well as first-in-human trials. FOMAT is dedicated to delivering high-quality services to its pharmaceutical and biotech clients while maintaining a strong focus on patient diversity.
“Our new Phase I unit represents a significant step forward in our mission to provide top-notch clinical services and improve diversity in clinical trials,” said Nicholas Focil, CEO of FOMAT Medical Research. “By bringing early-phase trials to underrepresented communities, we’re fostering a more inclusive approach to drug development.”
Enhancing Service Quality with State-of-the-Art Facilities
Located just outside Los Angeles, in Oxnard, California, the new Phase I unit offers facilities equipped for simple and complex trials across a variety of therapeutic areas. This expansion includes specialties such as Infectious Diseases, Neurology, Endocrinology, and Cardiology, ensuring that FOMAT can accommodate a broad spectrum of clinical trials.
The Phase I unit is vendor-qualified by leading CROs and Sponsors, underscoring FOMAT’s commitment to quality. This ensures that FOMAT is well-positioned to meet the growing demands of the clinical research industry while maintaining its focus on patient-centric services.
Commitment to Diversity in Clinical Research
A core mission for FOMAT is to improve patient diversity within clinical trials. By focusing on underserved populations, FOMAT aims to ensure that these communities have access to cutting-edge treatments and therapies from the earliest phases of development. This approach not only fosters inclusion but also contributes to more comprehensive and representative research outcomes.
For more details on FOMAT’s Phase I capabilities and how this expansion benefits both patients and the industry, read the full press release here.
About FOMAT Medical Research
As California’s largest research site network, FOMAT Medical Research partners with Sponsors and CROs to advance clinical research and improve patient outcomes. With a strong commitment to diversity, FOMAT continues to drive healthcare innovation across multiple therapeutic areas.